Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HK2 | P52789 | 5/20 | 0.34 |
| ▸ | HK1 | P19367 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Streptozosin SCHEMBL8714084 | 0.93 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL10424026 | 0.91 | LMNA (0.78) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Streptozosin SCHEMBL8193549 | 0.88 | LMNA (0.59) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL8539 | 0.84 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL1648834 | 0.84 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL11409484 | 0.84 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL11409480 | 0.84 | LMNA (0.64) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Streptozosin SCHEMBL22408645 | 0.84 | LMNA (0.70) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Chlorozotocin SCHEMBL19520816 | 0.83 | LMNA (0.63) | LMNAKDM4ECYP2D6CYP2C19ADRA2A | |
| Streptozosin SCHEMBL16896737 | 0.83 | LMNA (0.53) | LMNAKDM4ECYP2D6CYP2C19ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737617-B2 | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases | IBC PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-20170210825-A1 | MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE | BAYER IP GMBH (US) | 2017-07-27 | — | — | US | claimed |
| US-9624309-B2 | Monospecific and multispecific antibodies and method of use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-04-18 | — | — | US | claimed |
| US-20170088635-A1 | Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use | IBC PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | claimed |
| US-20170088619-A1 | Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells | IMMUNOMEDICS, INC. | 2017-03-30 | — | — | US | claimed |
| EP-2532676-B1 | Protease-regulated antibody | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | claimed |
| EP-2070548-B1 | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-EREG ANTIBODY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-01-18 | — | — | EP | claimed |
| EP-3066470-A2 | HUMANIZED ANTI-CEACAM5 ANTIBODY AND USES THEREOF | Immunomedics, Inc. (US) | 2016-09-14 | — | — | EP | claimed |
| US-20160243226-A1 | Combination Therapy With Anti-CD74 and Anti-CD20 Antibodies Provides Enhanced Toxicity to B-Cell Diseases | IBC PHARMACEUTICALS, INC. | 2016-08-25 | — | — | US | claimed |
| US-20150166669-A1 | ANTI-CD74 IMMUNOCONJUGATES AND METHODS OF USE | IMMUNOMEDICS INC (US) | 2015-06-18 | — | — | US | claimed |
| US-20050079184-A1 | Bispecific antibodies for inducing apoptosis of tumor and diseased cells | IMMUNOMEDICS, INC. (US) | 2005-04-14 | — | — | US | claimed |
| WO-2005014618-A2 | BISPECIFIC ANTIBODIES FOR INDUCING APOPTOSIS OF TUMOR AND DISEASED CELLS | IMMUNOMEDICS, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20050002945-A1 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | IMMUNOMEDICS, INC. | 2005-01-06 | — | — | US | claimed |
| US-20050003403-A1 | Polyvalent protein complex | IBC PHARMACEUTICALS, LLC | 2005-01-06 | — | — | US | claimed |
| WO-2004110390-A2 | ANTI-CD74 IMMUNOCONJUGATES AND METHODS | IMMUNOMEDICS, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-20040241158-A1 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004094613-A2 | POLYVALENT PROTEIN COMPLEX | IBC PHARMACEUTICALS (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040219203-A1 | Anti-CD74 immunoconjugates and methods | IMMUNOMEDICS, INC. | 2004-11-04 | — | — | US | claimed |
| WO-2004074434-A2 | METHODS AND COMPOSITIONS FOR ADMINISTERING THERAPEUTIC AND DIAGNOSTIC AGENTS | IMMUNOMEDICS, INC. (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040043030-A1 | Polymeric delivery systems | IMMUNOMEDICS, INC. | 2004-03-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088635-A1 | Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use | AKAP8L, DBNL, DOCK2 | LMNA 1138/4885KDM4E 2391/4885CYP2D6 4715/4885 |
| US-20050002945-A1 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | TST, GLUL, TGM3 | LMNA 4628/4885KDM4E 2537/4885CYP2D6 2694/4885 |
| US-20170088619-A1 | Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells | CD74, CD4, HLA-DRB1 | LMNA 4299/4885KDM4E 4164/4885CYP2D6 2172/4885 |
| US-20040241158-A1 | Methods and compositions for administering therapeutic and diagnostic agents | CD47, FCGR3B, HAVCR2 | LMNA 1130/4885KDM4E 4658/4885CYP2D6 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.